Reports document attempts at using other drugs for heparin neutralization. Methylene blue, hexadimethrine, vancomycin, and heparinase I are among drugs tested for heparin neutralization [115, 117, 118]. None of these drugs has proved equivalent to protamine in its safety pro le for reversal of heparin after CPB. One of these drugs, heparinase I, was compared with protamine in a multi- center, randomized, prospective trial; heparinase I had an inferior safety pro le after reversal of heparin at the end of CPB that was a result of increased transfusion and prolonged hospital stay in the heparinase group compared with the protamine group [118]. At this time, protamine is considered the gold standard for reversal of heparin anticoagulation. If protamine cannot be used, there are not enough data to make a recommendation regarding safety and ef cacy of any of the alternative heparin reversal agents. Class IIb Recommendation  Anticoagulation reversal when using heparin alter- natives and direct thrombin inhibitors: For patients requiring anticoagulation with bivalirudin who have excessive bleeding after CPB, a combination of modi ed ultra ltration, hemodialysis, and the administration of recombinant factor VIIa with blood product replacement may be considered to improve hemostasis in these extreme situations. (Level of Evidence C) Conclusion The ideal anticoagulation strategy for cardiac surgery with CPB in patients who cannot take heparin does not exist. Heparin and protamine remain the gold standard for anticoagulation therapy. A small subset of patients requires heparin alternatives for the conduct of CPB. Bivalirudin seems to offer the safest heparin alternative in this setting. This drug has a short half-life of approxi- mately 25 minutes. Nonetheless, coagulopathy occurs in bivalirudin-treated patients. There is no well-de ned reversal agent for bivalirudin, and patients with coagul- opathy and excessive bleeding require unusual in- terventions for hemorrhage control. Only anecdotal experience is available to address coagulopathy in cases of bivalirudin-related hemorrhage [68, 71]. Consensus suggests that a multifaceted approach offers the best chance of successful hemorrhage control for these pa- tients. Recombinant activated factor VII may be an important part of hemorrhage control but other in- terventions including modi ed ultra ltration, hemodialysis, and clotting factor replacement are also advocated [71]. References 1. Stoney WS. Evolution of cardiopulmonary bypass. Circu- lation 2009;119:2844 53. 2. Ferraris VA. Heroes and evidence. J Thorac Cardiovasc Surg 2002;124:11 3. 3. Bull BS, Korpman RA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg 1975;69:674 84. 4. Young JA, Kisker CT, Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of brin monomer. Ann Thorac Surg 1978;26:231 40. 5. Na S. Stabilized infective endocarditis and altered heparin responsiveness during cardiopulmonary bypass. World J Surg 2009;33:1862 7. 6. Garvin S, FitzGerald DC, Despotis G, Shekar P, Body SC. Heparin concentration-based anticoagulation for cardiac surgery fails to reliably predict heparin bolus dose re- quirements. Anesth Analg 2010;111:849 55. 7. Grima C. The effects of intermittent prebypass heparin dosing in patients undergoing coronary artery bypass grafting. Perfusion 2003;18:283 9. 8. Neema P, Sinha P, Rathod R. Activated clotting time during cardiopulmonary bypass: is repetition necessary during open heart surgery? Asian Cardiovasc Thorac Ann 2004;12: 47 52. 9. Shore-Lesserson L. Evidence based coagulation monitors: heparin monitoring, thromboelastography, and platelet function. Semin Cardiothorac Vasc Anesth 2005;9:41 52. 10. Machin D, Devine P. The effect of temperature and apro- tinin during cardiopulmonary bypass on three different methods of activated clotting time measurement. J Extra Corpor Technol 2005;37:265 71. 11. Leyvi G, Shore-Lesserson L, Harrington D, Vela-Cantos F, Hossain S. An investigation of a new activated clotting time MAX-ACT in patients undergoing extracorporeal circula- tion. Anesth Analg 2001;92:578 83. 12. Koster A, Fischer T, Praus M, et al. Hemostatic activation and in ammatory response during cardiopulmonary bypass: impact of heparin management. Anesthesiology 2002;97:837 41. 13. Despotis GJ, Joist JH, Hogue CW, et al. The impact of heparin concentration and activated clotting time moni- toring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1995;110:46 54. 14. Despotis GJ, Joist JH, Hogue CW, et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996;76:902 8. 15. Pappalardo F, Franco A, Crescenzi G, De Simone F, Torracca L, Zangrillo A. Anticoagulation management in patients undergoing open heart surgery by activated clot- ting time and whole blood heparin concentration. Perfusion 2006;21:285 90. 16. Hofmann B, Bushnaq H, Kraus FB, et al. Immediate effects of individualized heparin and protamine management on hemostatic activation and platelet function in adult patients undergoing cardiac surgery with tranexamic acid anti- brinolytic therapy. Perfusion 2013;28:412 8. 17. Newsome J, Stipanovich K, Flaherty S. Comparison of heparin administration using the Rapidpoint Coag and Hepcon HMS. J Extra Corpor Technol 2004;36:139 44. 18. Hansen R, Koster A, Kukucka M, Mertzlufft F, Kuppe H. A quick anti-Xa-activity-based whole blood coagulation assay for monitoring unfractionated heparin during Ann Thorac Surg 2018;105:650 62 ANTICOAGULATION DURING CARDIOPULMONARY BYPASS REPORT cardiopulmonary bypass: a pilot investigation. Anesth Analg 2000;91:533 8. 19. Hellstern P, Bach J, Simon M, Saggau W. Heparin moni- toring during cardiopulmonary bypass surgery using the one-step point-of-care whole blood anti-factor-Xa clotting assay Heptest-POC-Hi. J Extra Corpor Technol 2007;39: 81 6. 20. Gravlee GP, Haddon WS, Rothberger HK, et al. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation. J Thorac Cardiovasc Surg 1990;99: 518 27. 21. Gravlee GP, Rogers AT, Dudas LM, et al. Heparin man- agement protocol for cardiopulmonary bypass in uences postoperative heparin rebound but not bleeding. Anesthe- siology 1992;76:393 401. 22. Ichikawa J, Kodaka M, Nishiyama K, Hirasaki Y, Ozaki M, Komori M. Reappearance of circulating heparin in whole blood heparin concentration-based management does not correlate with postoperative bleeding after cardiac surgery. J Cardiothorac Vasc Anesth 2014;28:1015 9. 23. Bosch YP, Ganushchak YM, de Jong DS. Comparison of ACT point-of-care measurements: repeatability and agree- ment. Perfusion 2006;21:27 31. 24. Wallock M, Jeske WP, Bakhos M, Walenga JM. Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management test. Perfusion 2001;16:147 53. 25. Leyvi G, Zhuravlev I, Inyang A, et al. Arterial versus venous sampling for activated coagulation time measurements during cardiac surgery: a comparative study. J Cardiothorac Vasc Anesth 2004;18:573 80. 26. Searles B, Nasrallah F, Darling E, Yarcusko S. How does the age of a blood sample affect its activated clotting time? Comparison of eight different devices. J Extra Corpor Technol 2002;34:175 7. 27. Welsby IJ, McDonnell E, El-Moalem H, Stafford-Smith M, Toffaletti JG. Activated clotting time systems vary in pre- cision and bias and are not interchangeable when following heparin management protocols during cardiopulmonary bypass. J Clin Monit Comput 2002;17:287 92. 28. Raymond PD, Ray MJ, Callen SN, Marsh NA. Heparin monitoring during cardiac surgery. Part 2: calculating the overestimation of heparin by the activated clotting time. Perfusion 2003;18:277 81. 29. Patteril M, Stafford-Smith M, Toffaletti JG, Bute BP, Milano CA, Welsby IJ. Changing systems for measuring activated clotting times: impact on the clinical practice of heparin anticoagulation during cardiac surgery. Clin Chim Acta 2005;356:218 24. 30. Chavez JJ, Foley DE, Snider CC, et al. A novel thrombe- lastograph tissue factor/kaolin assay of activated clotting times for monitoring heparin anticoagulation during car- diopulmonary bypass. Anesth Analg 2004;99:1290 4. 31. Ganter MT, Monn A, Tavakoli R, et al. Monitoring activated clotting time for combined heparin and aprotinin applica- tion: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot. Eur J Cardiothorac Surg 2006;30:278 84. 32. Ganter MT, Monn A, Tavakoli R, Klaghofer R, Zollinger A, Hofer CK. Kaolin-based activated coagulation time measured by Sonoclot in patients undergoing cardiopul- monary bypass. J Cardiothorac Vasc Anesth 2007;21:524 8. 33. Watson H, Davidson S, Keeling D, Haemostasis and Thrombosis Task Force of the British Committee for Stan- dards in Haematology. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: sec- ond edition. Br J Haematol 2012;159:528 40. 34. Prechel MM, Walenga JM. Emphasis on the role of PF4 in the incidence, pathophysiology and treatment of heparin induced thrombocytopenia. Thromb J 2013;11:7. 35. Bircher AJ, Harr T, Hohenstein L, Tsakiris DA. Hypersen- sitivity reactions to anticoagulant drugs: diagnosis and management options. Allergy 2006;61:1432 40. 36. Centers for Disease Control. Acute allergic-type reactions among patients undergoing hemodialysis multiple states, 2007 2008. MMWR Morb Mortal Wkly Rep 2008;57:124 5. 37. Greinacher A. Heparin-induced thrombocytopenia. N Engl J Med 2015;373:252 61. 38. Warkentin TE. Clinical picture of heparin-induced throm- bocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia. Thromb Haemost 2016;116:813 22. 39. Kerendi F, Thourani VH, Puskas JD, et al. Impact of heparin-induced thrombocytopenia on postoperative out- comes after cardiac surgery. Ann Thorac Surg 2007;84: 1548 55. 40. Bennett-Guerrero E, Slaughter TF, White WD, et al. Pre- operative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery. J Thorac Cardiovasc Surg 2005;130:1567 72. 41. Kress DC, Aronson S, McDonald ML, et al. Positive heparin-platelet factor 4 antibody complex and cardiac surgical outcomes. Ann Thorac Surg 2007;83:1737 43. 42. Stribling WK, Slaughter TF, Houle TT, Sane DC. Beyond the platelet count: heparin antibodies as independent risk predictors. Am Heart J 2007;153:900 6. 43. Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: antith- rombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(Suppl):e495 530. 44. Selleng S, Haneya A, Hirt S, Selleng K, Schmid C, Greinacher A. Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia sched- uled for heart transplantation. Blood 2008;112:4024 7. 45. Warkentin TE, Sheppard JA. Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are reexposed to heparin. Blood 2014;123:2485 93. 46. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocy- topenia: American College of Chest Physicians evidence- based clinical practice guidelines (8th edition). Chest 2008;133(Suppl):340 80. 47. Lubenow N, Kempf R, Eichner A, Eichler P, Carlsson LE, Greinacher A. Heparin-induced thrombocytopenia: tem- poral pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 2002;122:37 42. 48. Warkentin TE, Kelton JG. A 14-year study of heparin- induced thrombocytopenia. Am J Med 1996;101:502 7. 49. Nuttall GA, Oliver WC, Santrach PJ, et al. Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmo- nary bypass: a prospective observational case series. Anesth Analg 2003;96:344 50. 50. Potzsch B, Klovekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med 2000;343: 515. 51. Warkentin TE, Arnold DM, Nazi I, Kelton JG. The platelet serotonin-release assay. Am J Hematol 2015;90:564 72. 52. Warkentin TE. Heparin-induced thrombocytopenia in crit- ically ill patients. Semin Thromb Hemost 2015;41:49 60. 53. Piednoir P, Allou N, Provenchere S, et al. Heparin-induced thrombocytopenia after cardiac surgery: an observational study of 1,722 patients. J Cardiothorac Vasc Anesth 2012;26: 585 90. 54. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006;4:759 65. 55. Lillo-Le Louet A, Boutouyrie P, Alhenc-Gelas M, et al. Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass. J Thromb Haemost 2004;2: 1882 8. 56. Cuker A, Arepally G, Crowther MA, et al. The HIT expert probability (HEP) score: a novel pre-test probability model 660 Ann Thorac Surg ANTICOAGULATION DURING CARDIOPULMONARY BYPASS 2018;105:650 62 REPORT for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost 2010;8:2642 50. 57. Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Pre- dictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood 2012;120:4160 7. 58. Warkentin TE, Kelton JG. Temporal aspects of heparin- induced thrombocytopenia. N Engl J Med 2001;344:1286 92. 59. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000;96:1703 8. 60. Pouplard C, May MA, Regina S, Marchand M, Fusciardi J, Gruel Y. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin- dependent antibodies. Br J Haematol 2005;128:837 41. 61. Warkentin TE, Greinacher A. Heparin-induced thrombo- cytopenia: recognition, treatment, and prevention: the sev- enth ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126(Suppl):311 37. 62. Berkun Y, Haviv YS, Schwartz LB, Shalit M. Heparin- induced recurrent anaphylaxis. Clin Exp Allergy 2004;34: 1916 8. 63. Grims RH, Weger W, Reiter H, Arbab E, Kranke B, Aberer W. Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: cross-reactivity does not depend on molecular weight. Br J Dermatol 2007;157:514 7. 64. Jappe U. Allergy to heparins and anticoagulants with a similar pharmacological pro le: an update. Blood Coagul Fibrinolysis 2006;17:605 13. 65. Koster A, Spiess B, Chew DP, et al. Effectiveness of biva- lirudin as a replacement for heparin during cardiopulmo- nary bypass in patients undergoing coronary artery bypass grafting. Am J Cardiol 2004;93:356 9. 66. Zucker ML, Koster A, Prats J, Laduca FM. Sensitivity of a modi ed ACT test to levels of bivalirudin used during cardiac surgery. J Extra Corpor Technol 2005;37:364 8. 67. Merry AF. Focus on thrombin: alternative anticoagulants. Semin Cardiothorac Vasc Anesth 2007;11:256 60. 68. Nagle EL, Tsu LV, Dager WE. Bivalirudin for anti- coagulation during hypothermic cardiopulmonary bypass and recombinant factor VIIa for iatrogenic coagulopathy. Ann Pharmacother 2011;45:e47. 69. Koster A, Dyke CM, Aldea G, et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin anti- bodies: results of the CHOOSE-ON trial. Ann Thorac Surg 2007;83:572 7. 70. Dyke CM, Smedira NG, Koster A, et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg 2006;131:533 9. 71. Stratmann G, deSilva AM, Tseng EE, et al. Reversal of direct thrombin inhibition after cardiopulmonary bypass in a pa- tient with heparin-induced thrombocytopenia. Anesth Analg 2004;98:1635 9. 72. Koster A, Buz S, Krabatsch T, et al. Effect of modi ed ul- tra ltration on bivalirudin elimination and postoperative blood loss after on-pump coronary artery bypass grafting: assessment of different ltration strategies. J Card Surg 2008;23:655 8. 73. Schwartz J, Winters JL, Padmanabhan A, et al. Guidelines on the use of therapeutic apheresis in clinical practice- evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher 2013;28:145 284. 74. Welsby IJ, Um J, Milano CA, Ortel TL, Arepally G. Plas- mapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. Anesth Analg 2010;110:30 5. 75. Warkentin TE, Sheppard JA, Chu FV, Kapoor A, Crowther MA, Gangji A. Plasma exchange to remove HIT antibodies: dissociation between enzyme-immunoassay and platelet activation test reactivities. Blood 2015;125: 195 8. 76. Addonizio VP, Fisher CA, Kappa JR, Ellison N. Prevention of heparin-induced thrombocytopenia during open heart surgery with iloprost (ZK36374). Surgery 1987;102:796 807. 77. Palatianos GM, Foroulis CN, Vassili MI, et al. Preoperative detection and management of immune heparin-induced thrombocytopenia in patients undergoing heart surgery with iloprost. J Thorac Cardiovasc Surg 2004;127:548 54. 78. Koster A, Kukucka M, Bach F, et al. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tiro ban. Anesthesiology 2001;94:245 51. 79. Tanigawa Y, Yamada T, Matsumoto K, Nakagawachi A, Torikai A, Sakaguchi Y. Non-recovery of ACT in a patient with heparin-induced thrombocytopenia type II during mitral valve replacement using argatroban anticoagulation. J Anesth 2013;27:951 5. 80. Genzen JR, Fareed J, Hoppensteadt D, et al. Prolonged elevation of plasma argatroban in a cardiac transplant pa- tient with a suspected history of heparin-induced throm- bocytopenia with thrombosis. Transfusion 2010;50:801 7. 81. Agarwal S, Ullom B, Al-Baghdadi Y, Okumura M. Chal- lenges encountered with argatroban anticoagulation during cardiopulmonary bypass. J Anaesthesiol Clin Pharmacol 2012;28:106 10. 82. Follis F, Filippone G, Montalbano G, et al. Argatroban as a substitute of heparin during cardiopulmonary bypass: a safe alternative? Interact Cardiovasc Thorac Surg 2010;10: 592 6. 83. Murphy GS, Marymont JH. Alternative anticoagulation management strategies for the patient with heparin- induced thrombocytopenia undergoing cardiac surgery. J Cardiothorac Vasc Anesth 2007;21:113 26. 84. Galeone A, Rotunno C, Guida P, et al. Monitoring incom- plete heparin reversal and heparin rebound after cardiac surgery. J Cardiothorac Vasc Anesth 2013;27:853 8. 85. Murray DJ, Brosnahan WJ, Pennell B, Kapalanski D, Weiler JM, Olson J. Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagu- lation tests and heparin assays. J Cardiothorac Vasc Anesth 1997;11:24 8. 86. Guo Y, Tang J, Du L, et al. Protamine dosage based on two titrations reduces blood loss after valve replacement sur- gery: a prospective, double-blinded, randomized study. Can J Cardiol 2012;28:547 52. 87. Shigeta O, Kojima H, Hiramatsu Y, et al. Low-dose prot- amine based on heparin-protamine titration method re- duces platelet dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1999;118:354 60. 88. Runge M, Moller CH, Steinbruchel DA. Increased accuracy in heparin and protamine administration decreases bleeding: a pilot study. J Extra Corpor Technol 2009;41:10 4. 89. Shore-Lesserson L, Reich DL, DePerio M. Heparin and protamine titration do not improve haemostasis in cardiac surgical patients. Can J Anaesth 1998;45:10 8. 90. Gundry SR, Drongowski RA, Coran AG, Kirsh MM, Klein MD. Failure of automated protamine titration to determine the protamine reversal dose of systemic heparin: comparison with other methods. Curr Surg 1986;43:110 2. 91. Wang J, Ma HP, Zheng H. Blood loss after cardiopulmonary bypass, standard versus titrated protamine: a meta-analysis. Neth J Med 2013;71:123 7. 92. Vonk AB, Veerhoek D, van den Brom CE, van Barneveld LJ, Boer C. Individualized heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery. J Cardiothorac Vasc Anesth 2014;28:235 41. 93. Koster A, Borgermann J, Gummert J, Rudloff M, Zittermann A, Schirmer U. Protamine overdose and its impact on coagulation, bleeding, and transfusions after Ann Thorac Surg 2018;105:650 62 ANTICOAGULATION DURING CARDIOPULMONARY BYPASS REPORT cardiopulmonary bypass: results of a randomized double- blind controlled pilot study. Clin Appl Thromb Hemost 2014;20:290 5. 94. Mochizuki T, Olson PJ, Szlam F, Ramsay JG, Levy JH. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg 1998;87:781 5. 95. Carr ME, Carr SL. At high heparin concentrations, prot- amine concentrations which reverse heparin anticoagulant effects are insuf cient to reverse heparin anti-platelet ef- fects. Thromb Res 1994;75:617 30. 96. Dunning J, Versteegh M, Fabbri A, et al. Guideline on an- tiplatelet and anticoagulation management in cardiac sur- gery. Eur J Cardiothorac Surg 2008;34:73 92. 97. Martin P, Horkay F, Gupta NK, Gebitekin C, Walker DR. Heparin rebound phenomenon much ado about nothing? Blood Coagul Fibrinolysis 1992;3:187 91. 98. Taneja R, Marwaha G, Sinha P, et al. Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery. Can J Anaesth 2009;56: 489 96. 99. Teoh KH, Young E, Blackall MH, Roberts RS, Hirsh J. Can extra protamine eliminate heparin rebound following car- diopulmonary bypass surgery? J Thorac Cardiovasc Surg 2004;128:211 9. 100. Nybo M, Madsen JS. Serious anaphylactic reactions due to protamine sulfate: a systematic literature review. Basic Clin Pharmacol Toxicol 2008;103:192 6. 101. Boigner H, Lechner E, Brock H, Golej J, Trittenwein G. Life threatening cardiopulmonary failure in an infant following protamine reversal of heparin after cardiopulmonary bypass. Paediatr Anaesth 2001;11:729 32. 102. Kimmel SE, Sekeres M, Berlin JA, Ellison N. Mortality and adverse events after protamine administration in patients undergoing cardiopulmonary bypass. Anesth Analg 2002;94:1402 8. 103. Welsby IJ, Newman MF, Phillips-Bute B, Messier RH, Kakkis ED, Stafford-Smith M. Hemodynamic changes after protamine administration: association with mortality after coronary artery bypass surgery. Anesthesiology 2005;102: 308 14. 104. Kimmel SE, Sekeres MA, Berlin JA, Goldberg LR, Strom BL. Adverse events after protamine administration in patients undergoing cardiopulmonary bypass: risks and predictors of under-reporting. J Clin Epidemiol 1998;51:1 10. 105. Ford SA, Kam PC, Baldo BA, Fisher MM. Anaphylactic or anaphylactoid reactions in patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth 2001;15:684 8. 106. Viaro F, Dalio MB, Evora PR. Catastrophic cardiovascular adverse reactions to protamine are nitric oxide/cyclic guanosine monophosphate dependent and endothelium mediated: should methylene blue be the treatment of choice? Chest 2002;122:1061 6. 107. Comunale ME, Maslow A, Robertson LK, Haering JM, Mashikian JS, Lowenstein E. Effect of site of venous prot- amine administration, previously alleged risk factors, and preoperative use of aspirin on acute protamine-induced pulmonary vasoconstriction. J Cardiothorac Vasc Anesth 2003;17:309 13. 108. Ocal A, Kiris I, Erdinc M, Peker O, Yavuz T, Ibrisim E. Ef- ciency of prostacyclin in the treatment of protamine- mediated right ventricular failure and acute pulmonary hypertension. Tohoku J Exp Med 2005;207:51 8. 109. Olinger GN, Becker RM, Bonchek LI. Noncardiogenic pul- monary edema and peripheral vascular collapse following cardiopulmonary bypass: rare protamine reaction? Ann Thorac Surg 1980;29:20 5. 110. Pretorius M, Scholl FG, McFarlane JA, Murphey LJ, Brown NJ. A pilot study indicating that bradykinin B2 re- ceptor antagonism attenuates protamine-related hypoten- sion after cardiopulmonary bypass. Clin Pharmacol Ther 2005;78:477 85. 111. Lee GM, Welsby IJ, Phillips-Bute B, Ortel TL, Arepally GM. High incidence of antibodies to protamine and protamine/ heparin complexes in patients undergoing cardiopulmo- nary bypass. Blood 2013;121:2828 35. 112. Bakchoul T, Zollner H, Amiral J, et al. Anti-protamine- heparin antibodies: incidence, clinical relevance, and path- ogenesis. Blood 2013;121:2821 7. 113. Vincent GM, Janowski M, Menlove R. Protamine allergy reactions during cardiac catheterization and cardiac sur- gery: risk in patients taking protamine-insulin preparations. Cathet Cardiovasc Diagn 1991;23:164 8. 114. Bernabei A, Gikakis N, Maione TE, et al. Reversal of heparin anticoagulation by recombinant platelet factor 4 and prot- amine sulfate in baboons during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1995;109:765 71. 115. Levy JH, Cormack JG, Morales A. Heparin neutralization by recombinant platelet factor 4 and protamine. Anesth Analg 1995;81:35 7. 116. Demma L, Levy JH. A case series of recombinant platelet factor 4 for heparin reversal after cardiopulmonary bypass. Anesth Analg 2012;115:1273 8. 117. Kikura M, Lee MK, Levy JH. Heparin neutralization with methylene blue, hexadimethrine, or vancomycin after car- diopulmonary bypass. Anesth Analg 1996;83:223 7. 118. Stafford-Smith M, Lefrak EA, Qazi AG, et al. Ef cacy and safety of heparinase I versus protamine in patients under- going coronary artery bypass grafting with and without cardiopulmonary bypass. Anesthesiology 2005;103:229 40. 662 Ann Thorac Surg ANTICOAGULATION DURING CARDIOPULMONARY BYPASS 2018;105:650 62 REPORT